Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

In one hand, a slender young woman holds up a bottle of clear liquid. The words “Skinny” and “GLP-1” — a new class of weight loss drugs — are visible on the label. In the other hand, she raises up a ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

New studies to be presented at the American Heart Association meeting focus on disparities in Wegovy prescriptions and ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

Opens in a new tab or window SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on ...

Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Recent studies have found that Ozempic could lead to more muscle mass loss than traditional weight loss methods.

The Danish firm’s patents for semaglutide, the active pharmaceutical ingredient ... are likely to have a better profile in ...

Weight-loss drugs, particularly newer options like GLP-1 receptor agonists, are revolutionising the treatment of obesity and ...